

1                   **HOUSE OF REPRESENTATIVES - FLOOR VERSION**

2                   STATE OF OKLAHOMA

3                   1st Session of the 60th Legislature (2025)

4 COMMITTEE SUBSTITUTE  
FOR  
5 HOUSE BILL NO. 1416

By: West (Josh) of the House

6                   and

7                   Rosino of the Senate

10                  COMMITTEE SUBSTITUTE

11                  An Act relating to non-opioid treatment; defining  
12                  terms; authorizing insurers to amend preferred drug  
13                  lists; allowing for discretion in drug treatment;  
14                  prohibiting certain drugs over others for treatment;  
15                  allowing coverage of drugs once approved by the  
16                  United States Food and Drug Administration;  
17                  authorizing coverage of non-opioid drugs; authorizing  
18                  reimbursement to hospitals for non-opioid treatment;  
19                  providing for codification; and providing an  
20                  effective date.

21 BE IT ENACTED BY THE PEOPLE OF THE STATE OF OKLAHOMA:

22                  SECTION 1.        NEW LAW        A new section of law to be codified

23                  in the Oklahoma Statutes as Section 1313.1 of Title 74, unless there  
24                  is created a duplication in numbering, reads as follows:

25                  A. As used in this section:

26                  1. "Group insurance plan" means a group insurance plan that  
27                  covers state employees;

1       2. "Health care prescriber" means an individual authorized by  
2 law to prescribe drugs;

3       3. "Insurer" means an insurer that offers a group insurance  
4 plan; and

5       4. "Non-opioid treatment" means a drug or biological product  
6 that is indicated to produce analgesia without acting on the body's  
7 opioid receptors, for which there is no other drug or product that  
8 is rated as therapeutically equivalent under the Food and Drug  
9 Administration's most recent publication of "Approved Drug Products  
10 with Therapeutic Equivalence Evaluations".

11      B. Except as otherwise provided in this section, an insurer,  
12 for purposes of offering a group insurance plan, may adopt or amend  
13 a state preferred drug list (PDL).

14      C. 1. In establishing and maintaining the PDL, the insurer  
15 shall ensure that a non-opioid drug approved by the United States  
16 Food and Drug Administration for the treatment or management of pain  
17 is not disadvantaged or discouraged with respect to coverage  
18 relative to an opioid or narcotic drug for the treatment or  
19 management of pain on the PDL.

20      2. Paragraph 1 of this subsection does not prohibit an opioid  
21 medication from being preferred over other opioid medications, or a  
22 non-opioid medication from being preferred over other non-opioid  
23 medications.

1       D. This section applies to a non-opioid drug treatment as  
2 defined in paragraph 4 of subsection A of this section that has been  
3 reviewed and approved for coverage by a group insurance plan or  
4 insurer as defined in subsection A of this section. This section  
5 also applies to drugs being provided under a contract between the  
6 insurer and a pharmacy benefits manager for purposes of a group  
7 insurance plan.

8           SECTION 2. This act shall become effective November 1, 2025.  
9

10          COMMITTEE REPORT BY: COMMITTEE ON HEALTH AND HUMAN SERVICES  
OVERSIGHT, dated 02/26/2025 - DO PASS, As Amended.  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24